Microbial Translocation Induces an Intense Proinflammatory Response in PatientsWith Visceral Leishmaniasis and HIV Type 1 Coinfection

Imagem de Miniatura
Arquivos
art_LINDOSO_Microbial_Translocation_Induces_an_Intense_Proinflammatory_Response_in_2013.PDF (1.06 MB)
Citações na Scopus
32
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
SANTOS-OLIVEIRA, Joanna R.
REGIS, Eduardo G.
GIACOIA-GRIPP, Carmem B. W.
VALVERDE, Joanna G.
ALEXANDRINO-DE-OLIVEIRA, Priscilla
OLIVEIRA-NETO, Manoel P.
GUERRA, Jorge O.
GRINSZTEJN, Beatriz
Citação
JOURNAL OF INFECTIOUS DISEASES, v.208, n.1, p.57-66, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background. Leishmania infection is a cofactor in the heightened cellular activation observed in patients with American visceral leishmaniasis and human immunodeficiency virus type 1 (HIV) infection, with or without progression to AIDS (AVL/HIV). Thus, the persistence of a high parasite load despite antileishmanial therapy could be responsible for the continued immune stimulation. Methods. CD8(+) T cells expressing CD38, parasite load, lipopolysaccharide (LPS), soluble CD14, macrophage migration inhibitory factor (MIF), intestinal fatty acid-binding protein (IFABP), and proinflammatory cytokines (interleukin 1 beta, interleukin 6, interleukin 8, interleukin 17, interferon gamma, and tumor necrosis factor) were measured in 17 patients with AVL/HIV, 16 with HIV, and 14 healthy subjects (HS). Results. Lower Leishmania parasitemia was observed after antileishmanial and antiretroviral therapies. However, higher levels of CD38(+) on CD8(+) T cells were observed in both clinical phases of leishmaniasis, compared with HIV cases. AVL/HIV and HIV patients showed higher levels of LPS and IFABP than HS. Proinflammatory cytokine levels were significantly augmented in patients with active coinfection, as well as those with remission of Leishmania infection. LPS levels and Leishmania infection were positively correlated with CD38 expression on CD8(+) T cells and with IL-6 and IL-8 levels. Conclusions. LPS levels along with the immune consequences of Leishmania infection were associated with elevated cellular activation in coinfected patients. As a consequence, secondary chemoprophylaxis for leishmaniasis or even the use of antiinflammatory drugs or antibiotics may be considered for improving the prognosis of AVL/HIV.
Palavras-chave
visceral leishmaniasis-HIV/AIDS coinfection, microbial translocation, inflammatory cytokines
URI
https://observatorio.fm.usp.br/handle/OPI/2117
Referências
  1. Alexandrino-de-Oliveira P, 2010, MEM I OSWALDO CRUZ, V105, P692, DOI 10.1590/S0074-02762010000500016
  2. Alexandrino-de-Oliveira P, 2010, BMC INFECT DIS, V10, P35863
  3. Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
  4. Antinori S, 2007, CLIN INFECT DIS, V44, P1602, DOI 10.1086/518167
  5. Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
  6. Balkhair A, 2008, INT J INFECT DIS, V12, P111, DOI 10.1016/j.ijid.2007.04.009
  7. Barreto-De-Souza V, 2006, J INFECT DIS, V194, P846, DOI 10.1086/506618
  8. Bernier R, 1998, J IMMUNOL, V160, P2881
  9. Brasil Ministerio da Saude Departamento de DST Aids e hepatites virais, PROT CLIN DIR TER AD
  10. Brasil Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Vigilancia Epidemiologica, 2006, MAN VIG CONTR LEISHM
  11. Brenchley JM, 2012, ANNU REV IMMUNOL, V30, P149, DOI 10.1146/annurev-immunol-020711-075001
  12. Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
  13. Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
  14. Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
  15. Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1179/096805100101532063
  16. Casado JL, 2001, EUR J CLIN MICROBIOL, V20, P202, DOI 10.1007/s10096-001-8082-z
  17. Connolly NC, 2005, AIDS REV, V7, P168
  18. Cooke KR, 2002, J ENDOTOXIN RES, V8, P441, DOI 10.1179/096805102125001046
  19. Cota GF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001153
  20. Doisne JM, 2004, J IMMUNOL, V173, P2410
  21. Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549
  22. Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052
  23. Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
  24. Gonzalez VD, 2009, J VIROL, V83, P11407, DOI 10.1128/JVI.01211-09
  25. Goto H, 2009, REV I MED TROP, V51, P241, DOI 10.1590/S0036-46652009000500002
  26. Hicks L, 2009, EUR J GASTROEN HEPAT, V21, P117, DOI 10.1097/MEG.0b013e32830e6fdb
  27. Rodrigues Denise do Socorro S., 2003, Braz J Infect Dis, V7, P161, DOI 10.1590/S1413-86702003000200010
  28. Lee PI, 2009, J INFECT DIS, V199, P1664, DOI 10.1086/598953
  29. Lieberman JM, 1997, SURGERY, V121, P335, DOI 10.1016/S0039-6060(97)90363-9
  30. Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83
  31. Baba Chalamalasetty Sreenivasa, 2006, Indian J Gastroenterol, V25, P309
  32. McCoy JJ, 1998, MOL BIOCHEM PARASIT, V95, P251, DOI 10.1016/S0166-6851(98)00112-1
  33. Medrano FJ, 1998, CLIN EXP IMMUNOL, V114, P403, DOI 10.1046/j.1365-2249.1998.00733.x
  34. Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
  35. Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068
  36. Mock DJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002635
  37. Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852
  38. Rabello A, 2003, ANN TROP MED PARASIT, V97, P17, DOI 10.1179/000349803225002507
  39. Saha S, 2006, INDIAN J MED RES, V123, P245
  40. Sandler NG, 2011, GASTROENTEROLOGY, V141, P1220, DOI 10.1053/j.gastro.2011.06.063
  41. Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
  42. Senent SG, 2009, GASTROENTEROL HEPATO, V32, P176, DOI 10.1016/j.gastrohep.2008.09.021
  43. Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
  44. Sinha PK, 2006, INDIAN J MED RES, V123, P197
  45. Sousa-Gomes ML, 2011, EPIDEMIOL SERV SAUDE, V20, P519
  46. Weirather JL, 2011, J CLIN MICROBIOL, V49, P3892, DOI 10.1128/JCM.r00764-11
  47. Wolday D, 1998, SCAND J INFECT DIS, V30, P29
  48. Zhao CQ, 2004, CLIN IMMUNOL, V113, P81, DOI 10.1016/j.clim.2004.06.003
  49. Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - LIM/38
Artigos e Materiais de Revistas Científicas - ODS/03